Literature DB >> 35468938

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.

Shan Zhu1, Chunliu Zhang2, Dongyan Cao1, Jing Bai2, Shuangni Yu3, Jie Chen3, Jing Wang4, Tong Ren1, Jiaxin Yang1, Mei Yu1, Xiao Xiao5, Yuhua Gong2, Yanfang Guan2, Peiling Li6, Ying Yue7, Rutie Yin8, Yongjun Wang9, Ruifang An10, Ge Lou11, Jianlin Yuan12, Guonan Zhang13, Xuefeng Xia2, Ling Yang14, Yang Xiang15.   

Abstract

Epithelial ovarian cancer (EOC) is classified into five major histotypes: high-grade serous (HGSOC), low-grade serous (LGSOC), clear cell (CCOC), endometrioid (ENOC), and mucinous (MOC). However, the landscape of molecular and immunological alterations in these histotypes, especially LGSOC, CCOC, ENOC, and MOC, is largely uncharacterized. We collected 101 treatment-naive EOC patients. The resected tumor tissues and paired preoperative peripheral blood samples were collected and subjected to target sequencing of 1021 cancer-associated genes and T cell repertoire sequencing. Distinct characteristics of mutations were identified among the five histotypes. Furthermore, tumor mutation burden (TMB) was found to be higher in CCOC and ENOC, but lower in LGSOC and HGSOC. Alterations associated with DNA damage repair (DDR) pathways and homologous recombination deficiencies (HRD) were prevalent in five histotypes. CCOC demonstrated increased level of T cell clonality compared with HSGOC. Interestingly, the proportion of the 100 most common T cell clones was associated with TMB and tumor neoantigen burden in CCOC, highlighting more sensitive anti-tumor responses in this histotype, which was also evidenced by the enhanced convergent recombination of T cell clones. These findings shed light on the molecular traits of genomic alteration and T cell repertoire in the five major EOC histotypes and may help optimize clinical management of EOC with different histotypes.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35468938     DOI: 10.1038/s41388-022-02277-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

Review 1.  Epithelial ovarian cancer.

Authors:  Stephanie Lheureux; Charlie Gourley; Ignace Vergote; Amit M Oza
Journal:  Lancet       Date:  2019-03-23       Impact factor: 79.321

2.  Intensive surgical and chemotherapeutic management of advanced ovarian cancer.

Authors:  C T Griffiths; A F Fuller
Journal:  Surg Clin North Am       Date:  1978-02       Impact factor: 2.741

3.  Clinicopathological parameters and survival of invasive epithelial ovarian cancer by histotype and disease stage.

Authors:  Aihua Lan; Gong Yang
Journal:  Future Oncol       Date:  2019-05-29       Impact factor: 3.404

4.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

Review 5.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

Authors:  Stephanie Lheureux; Marsela Braunstein; Amit M Oza
Journal:  CA Cancer J Clin       Date:  2019-05-17       Impact factor: 508.702

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 7.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

8.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.

Authors:  Karen Hoffmann; Hilmar Berger; Hagen Kulbe; Sukanija Thillainadarasan; Hans-Joachim Mollenkopf; Tomasz Zemojtel; Eliane Taube; Silvia Darb-Esfahani; Mandy Mangler; Jalid Sehouli; Radoslav Chekerov; Elena I Braicu; Thomas F Meyer; Mirjana Kessler
Journal:  EMBO J       Date:  2020-02-03       Impact factor: 11.598

10.  Copy number signatures and mutational processes in ovarian carcinoma.

Authors:  Geoff Macintyre; Teodora E Goranova; Dilrini De Silva; Darren Ennis; Anna M Piskorz; Matthew Eldridge; Daoud Sie; Liz-Anne Lewsley; Aishah Hanif; Cheryl Wilson; Suzanne Dowson; Rosalind M Glasspool; Michelle Lockley; Elly Brockbank; Ana Montes; Axel Walther; Sudha Sundar; Richard Edmondson; Geoff D Hall; Andrew Clamp; Charlie Gourley; Marcia Hall; Christina Fotopoulou; Hani Gabra; James Paul; Anna Supernat; David Millan; Aoisha Hoyle; Gareth Bryson; Craig Nourse; Laura Mincarelli; Luis Navarro Sanchez; Bauke Ylstra; Mercedes Jimenez-Linan; Luiza Moore; Oliver Hofmann; Florian Markowetz; Iain A McNeish; James D Brenton
Journal:  Nat Genet       Date:  2018-08-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.